Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus erlotinib vs placebo plus erlotinib in MET-positive NSCLC
CTR20130970Phase 3Suspended
- Sponsor
- Roche
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of onartuzumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Oct 2014; status: suspended.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20130970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130970.